Tyra Biosciences, Inc. has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, with expected gross proceeds of approximately $400.0 million. The offering is anticipated to close on September 15, 2026.

Key Details

  • Gross Proceeds: Approximately $400.0 million before deducting underwriting discounts and commissions.
  • Offering Structure: The offering includes 9,079,000 shares of common stock at a price of $22.03 per share and 9,078,529 pre-funded warrants at a price of $22.029 per warrant.
  • Use of Proceeds: Funds will be used to advance its "dabogratinib 3x3" development strategy and support preclinical programs, working capital, and other corporate purposes.
  • Lead Underwriters: The offering is managed by Jefferies, Guggenheim Securities, Cantor Fitzgerald & Co., and Barclays Capital Inc.